Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2012

View Archived Issues

Multiple insulin degludec trials presented at recent conferences

Canadian study links gene's copy number to ankylosing spondylitis

New model allows assessment of two islet preparations in one primate

Novel apoptosis inducers created at IMPACT Therapeutics

First-in-human data presented on oncolytic BAY-1000394

Simcere presents new calcium channel blockers/acetylcholinesterase inhibitors

Eli Lilly designs novel metabotropic glutamate receptor antagonists

Sunovion reports Canadian approval of once-daily schizophrenia therapy

Anergis achieves preclinical milestones

Civitas Therapeutics advances inhaled levodopa formulation to phase IIa

Sublingual drug for sleep disorders approved in Europe

AstraZeneca and Dainippon Sumitomo jointly patent new oncolytics

New tau-detecting diagnostics developed by GE Healthcare and Medi-Physics

Portola updates on trial of universal factor Xa inhibitor antidote

Phase II study tests iron chelator in adults with transfusional iron overload

EPFL reports novel antibacterials

Dyax discontinues trial of drug for ACE inhibitor-induced angioedema

Wilex oral uPA inhibitor is efficacious in proof-of-concept study

Lysogene advances gene therapy study in Sanfilippo type A syndrome

Janssen files applications to extend Zytiga indication

Debiopharm and Ascepion enter license agreement for multikinase inhibitor

Bavarian Nordic receives government contract for MVA-BN-based vaccines

Valeant Pharmaceuticals to acquire oral health product company

Tosedostat studied for elderly patients with AML or high-risk MDS

First clinical data disclosed on Bristol-Myers Squibb drug for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...